Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sienna Labs Appoints Clint Carnell to Board of Directors

RM, BIOGY

SAN DIEGO, Jan. 8, 2015 /PRNewswire/ -- Sienna Labs, Inc., the foremost experts in the cutting edge field of biophysics utilizing plasmonic nanoparticles, is pleased to announce the appointment of Clint Carnell to the Board of Directors. 

Mr. Carnell brings extensive leadership experience to Sienna Labs with a successful 20+ year track record of building companies and creating shareholder value. Clint recently served as an advisor to Covidien plc as executive in residence.  From 2011-2014 he was President, Chief Executive and Chairman of myoscience, inc., a silicon valley based medical device company specializing in using cold to treat peripheral nerve conditions in pain and aesthetics.  From 2005-2011, Clint was a key member of the executive team responsible for the turnaround of Thermage, Inc. including a successful IPO and responsibility for the integration of Reliant to create Solta Medical, Inc. as Chief Operating Officer.  Solta later sold to Valeant Pharmaceuticals for 280 million dollars.  Clint holds a bachelor of arts degree from Duke University.

"I am very pleased to have attracted such a talented leader to the Sienna Labs team," said Todd Harris. "Clint's experience raising capital, building successful leadership teams, and brokering partnership and M&A deals will help us maximize the value of our technology for the benefit of physicians and patients."

About Sienna Labs
Sienna Labs, a leader in the cutting edge field of biophysics, is developing novel approaches to treat skin based on the science of plasmonic resonance. The team of world renowned scientists, entrepreneurs, and physicians have invented a breakthrough technology called Targeted Plasmonic Therapy (TPT).The company's innovative approach uses the current existing base of energy devices in combination with their proprietary plasmonic nanoparticles to target select microstructures in the skin enabling a broad portfolio of indications. The first two anticipated indications for the TPT platform will be the safe and effective removal of light-pigmented hair (gray, red, blonde, white) and treatment of acne. The company is based in San Diego, CA. For more information, visit www.SiennaLabs.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sienna-labs-appoints-clint-carnell-to-board-of-directors-300017924.html

SOURCE Sienna Labs



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today